The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Western District of Texas on behalf of shareholders of Natera, Inc. who purchased shares between February 26, 2020 and April 19, 2022.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:
(1) the Company’s non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until June 27, 2022 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.